![]() JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. | ![]() Melinta Therapeutics Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections.
| ![]() GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. | ||
Founding Date | Founding Date 2006 | Founding Date 1975 | Founding Date 2000 | Founding Date 2012 |
Type | Type Private | Type Public | Type Private | Type Public |
Tags | ||||
Locations | Locations Corsham, GB HQ | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations Morristown, US HQ New Haven, US | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB |
Employees | Employees 903% decrease | Employees 934 | Employees 1712% increase | Employees 352106% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 533.9 m | Valuation ($) N/A | Valuation ($) 4.4 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥40.3b (FY, 2026) | Revenue (est.) N/A | Revenue (est.) $194.7m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods ¥7.6b (FY, 2026) | Cost of goods N/A | Cost of goods $3.3m (FY, 2021) |
Net income | Net income N/A | Net income ¥2.2b (FY, 2026) | Net income N/A | Net income ($303.1m) (FY, 2021) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 519.2m | Total funding raised $ 88.7m |

JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View company
Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections.
View company
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View company